Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN003 in advanced solid tumors
NCT05494918Phase 1Completed
- Sponsor
- Alphamab Oncology
- Start
- Sep 2022
- Primary completion
- Apr 2025
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anbenitamab repodatecan in solid tumor, sponsored by Alphamab Oncology. Primary endpoints: Maximum Tolerated Dose at 1 year, Recommended Phase 2 Dose at 1 year and 2 more. Started Sep 2022; status: completed.
02
Drugs
anbenitamab repodatecan
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05494918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05494918.